Novartis has entered into an agreement to acquire Mariana Oncology, a preclinical-stage biotechnology company based in Watertown, MA focused on developing radioligand therapies (RLTs) to treat cancers. The transaction expands Novartis’ RLT pipeline and research infrastructure and clinical supply capabilities.
 Under the agreement, Novartis will pay $1 billion upfront and additional $750 million in payments upon completion of pre-specified milestones. The acquisition includes a portfolio ...